| Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ... The Lancet Oncology 18 (5), 587-598, 2017 | 301 | 2017 |
| Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis) S Kummar, G O'Sullivan Coyne, KT Do, B Turkbey, PS Meltzer, E Polley, ... Journal of Clinical Oncology 35 (14), 1561-1569, 2017 | 183 | 2017 |
| Curcumin induces apoptosis-independent death in oesophageal cancer cells G O'Sullivan-Coyne, GC O'sullivan, TR O'Donovan, K Piwocka, ... British journal of cancer 101 (9), 1585-1595, 2009 | 183 | 2009 |
| Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma A Rajan, CR Heery, A Thomas, AL Mammen, S Perry, G O’Sullivan Coyne, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 114 | 2019 |
| Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH GOS Coyne, N Takebe, AP Chen Current problems in cancer 41 (3), 182-193, 2017 | 91 | 2017 |
| Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. CR Heery, GH O'Sullivan Coyne, RA Madan, J Schlom, ... Journal of Clinical Oncology 32 (15_suppl), 3064-3064, 2014 | 84 | 2014 |
| Molecular features of cancers exhibiting exceptional responses to treatment DA Wheeler, N Takebe, T Hinoue, KA Hoadley, MF Cardenas, ... Cancer cell 39 (1), 38-53. e7, 2021 | 76 | 2021 |
| Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer S Kummar, JL Wade, AM Oza, D Sullivan, AP Chen, DR Gandara, J Ji, ... Investigational new drugs 34, 355-363, 2016 | 72 | 2016 |
| An overview of the NCI precision medicine trials—NCI MATCH and MPACT K Do, GOS Coyne, AP Chen Chinese clinical oncology 4 (3), 31-31, 2015 | 69 | 2015 |
| Nivolumab: promising survival signal coupled with limited toxicity raises expectations GOS Coyne, RA Madan, JL Gulley Journal of clinical oncology: official journal of the American Society of …, 2014 | 64 | 2014 |
| PARP inhibitors in reproductive system cancers: current use and developments G O’Sullivan Coyne, AP Chen, R Meehan, JH Doroshow Drugs 77 (2), 113-130, 2017 | 53 | 2017 |
| Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) AR Naqash, GH O’Sullivan Coyne, N Moore, E Sharon, N Takebe, ... J Clin Oncol 39 (15_suppl), 11519, 2021 | 46 | 2021 |
| Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023) AR Kim, Y Lu, SH Okuno, D Reinke, O Maertens, J Perentesis, M Basu, ... Sarcoma, 2020 | 45 | 2020 |
| Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors N Takebe, AR Naqash, G O'Sullivan Coyne, S Kummar, K Do, A Bruns, ... Clinical Cancer Research 27 (14), 3834-3844, 2021 | 39 | 2021 |
| The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas S Jackson, EH Baker, AM Gross, P Whitcomb, A Baldwin, J Derdak, ... Neuro-Oncology Advances 2 (1), vdaa095, 2020 | 35 | 2020 |
| Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E2-independent mechanisms BM Deasy, G O’Sullivan-Coyne, TR O’Donovan, SL McKenna, ... Cancer letters 256 (2), 246-258, 2007 | 32 | 2007 |
| Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with … CR Heery, GH O'Sullivan Coyne, JL Marte, H Singh, LM Cordes, ... Journal of Clinical Oncology 33 (15_suppl), 3055-3055, 2015 | 29 | 2015 |
| Phase II study of atezolizumab in patients with alveolar soft part sarcoma GO Coyne, E Sharon, N Moore, R Meehan, N Takebe, L Juwara, ... Connective Tissue Oncology Society Annual Meeting, 14-17, 2018 | 28 | 2018 |
| Molecular profiling-based assignment of cancer therapy (NCI-MPACT): A randomized multicenter phase II trial AP Chen, S Kummar, N Moore, LV Rubinstein, Y Zhao, PM Williams, ... JCO Precision Oncology 5, 133-144, 2021 | 27 | 2021 |
| Adding fuel to the fire: Immunogenic intensification G O’Sullivan Coyne, JL Gulley Human vaccines & immunotherapeutics 10 (11), 3306-3312, 2014 | 27 | 2014 |
